<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01063972</url>
  </required_header>
  <id_info>
    <org_study_id>5R01CA101963-07</org_study_id>
    <secondary_id>5R01CA101963-07</secondary_id>
    <nct_id>NCT01063972</nct_id>
  </id_info>
  <brief_title>Smoking Cessation in Rural Hospitals</brief_title>
  <official_title>Centralized Disease Management for Rural Hospitalized Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edward Ellerbeck, MD, MPH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our long-term goal is to improve smoking cessation treatment for rural smokers. The objective
      is to assess the effectiveness of a centralized disease management program for hospitalized
      smokers that coordinates care across treatment settings and links smokers to existing
      resources. Our central hypothesis is that Centralized Disease Management (CDM) will increase
      the use of smoking cessation treatments and lead to greater long term smoking cessation than
      Counseling alone. Demonstrating the effectiveness of a disease management program and
      identifying the critical components of such a program will provide a basis for improving the
      utilization of existing smoking cessation resources while enhancing the treatment of rural
      hospitalized smokers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study will use a randomized clinical trial design to examine the effectiveness
      of centralized disease management (CDM) versus counseling alone (C) for smoking cessation.
      Hospitalized smokers in 30 rural critical access hospitals will be randomly assigned to
      either CDM (n=303) or C (n=303). Participants in both arms of the study will receive
      in-hospital smoking cessation counseling via telephone followed by 4 outpatient
      telephone-based counseling calls. The content and timing of these counseling calls are
      designed to emulate models of smoking cessation counseling that have been previously shown to
      be effective for hospitalized smokers. For recipients assigned to CDM, the counseling will be
      streamlined to allow time on the calls for specific disease management interventions,
      including screening for contraindications to pharmacotherapy and linking medication choices
      to the smoker's insurance coverage. After completing calls with CDM participants, the Tobacco
      Treatment Specialists will coordinate therapy with the patient's health care providers by
      providing them with brief consultation reports, prepared order sheets for inpatient
      treatment, and outpatient prescription requests. Six months postdischarge, participants in
      both groups will be contacted again, and persistent or relapsed smokers will be offered
      another cycle of the C or CDM intervention.

      Assessments will be conducted at baseline and at months 3, 6, and 12. The primary outcome of
      interest will be biochemically verified 7-day point prevalence abstinence at 12 months.
      Secondary endpoints include number of quit attempts and number of cigarettes smoked (among
      continuing smokers), pharmacotherapy utilization, duration of pharmacotherapy utilization,
      and the extent of discussions with the healthcare provider. We will also examine the marginal
      cost-effectiveness of the intervention.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With 7-day Point Prevalence Abstinence From Cigarettes, Validated</measure>
    <time_frame>12 months</time_frame>
    <description>Participant-reported 7-day point prevalence abstinence from cigarettes, validated by salivary cotinine (&lt; 15ng/ml) or proxy. Participants who did not respond to the survey were considered current smokers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With 7-day Point Prevalence Abstinence at 3 Months, Self-reported</measure>
    <time_frame>3 months</time_frame>
    <description>7-day point prevalence abstinence at 3 months, self-reported. Participants who did not respond were considered smokers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With 7-day Point Prevalence Abstinence at 6 Months, Self-reported</measure>
    <time_frame>6 months</time_frame>
    <description>7-day point prevalence abstinence at 6 months, self-reported. Participants who did not respond were considered smokers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With 7-day Point Prevalence Abstinence at 12 Months, Self-reported</measure>
    <time_frame>12 months</time_frame>
    <description>7-day point prevalence abstinence at 12 months, self-reported. Participants who did not respond were considered smokers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Utilization of Smoking Cessation Pharmacotherapy During First 6 Months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Utilization of Smoking Cessation Pharmacotherapy Between 6 and 12 Months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">606</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Experimental 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: 1 Centralized disease management</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: 2 Counseling alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Centralized disease management (CDM)</intervention_name>
    <description>Centralized Disease Management (CDM) arm will receive smoking cessation counseling with coordination of pharmacotherapy with their insurance coverage and their health care provider</description>
    <arm_group_label>Experimental 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Counseling (C)</intervention_name>
    <description>Counseling (C) arm will receive counseling without the care coordination services.</description>
    <arm_group_label>Experimental 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized in a participating rural hospital

          -  Aged 18 years or older

          -  Smoke cigarettes on &gt;25 of the last 30 days

          -  Have a home address and telephone

          -  Willing to participate in phone assessments

        Exclusion Criteria:

          -  Terminal medical condition with life expectancy &lt;1 year

          -  Pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Ellerbeck, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 4, 2010</study_first_submitted>
  <study_first_submitted_qc>February 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2010</study_first_posted>
  <results_first_submitted>March 12, 2019</results_first_submitted>
  <results_first_submitted_qc>April 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 8, 2019</results_first_posted>
  <last_update_submitted>April 4, 2019</last_update_submitted>
  <last_update_submitted_qc>April 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Edward Ellerbeck, MD, MPH</investigator_full_name>
    <investigator_title>Professor, Chairman Preventive Medicine</investigator_title>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Centralized Disease Management (CDM)</title>
          <description>Experimental: 1 Centralized disease management
Centralized disease management (CDM): Centralized Disease Management (CDM) arm will receive smoking cessation counseling with coordination of pharmacotherapy with their insurance coverage and their health care provider</description>
        </group>
        <group group_id="P2">
          <title>Counseling (C)</title>
          <description>Experimental: 2 Counseling alone
Counseling (C): Counseling (C) arm will receive counseling without the care coordination services.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="310"/>
                <participants group_id="P2" count="296"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="296">Participants who were deceased or incarcerated were excluded.</participants>
                <participants group_id="P2" count="284">Participants who were deceased or incarcerated were excluded.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incarcerated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Centralized Disease Management (CDM)</title>
          <description>Experimental: 1 Centralized disease management
Centralized disease management (CDM): Centralized Disease Management (CDM) arm will receive smoking cessation counseling with coordination of pharmacotherapy with their insurance coverage and their health care provider</description>
        </group>
        <group group_id="B2">
          <title>Counseling (C)</title>
          <description>Experimental: 2 Counseling alone
Counseling (C): Counseling (C) arm will receive counseling without the care coordination services.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="310"/>
            <count group_id="B2" value="296"/>
            <count group_id="B3" value="606"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.6" spread="12.89"/>
                    <measurement group_id="B2" value="51.0" spread="11.82"/>
                    <measurement group_id="B3" value="50.8" spread="12.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="383"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="285"/>
                    <measurement group_id="B2" value="287"/>
                    <measurement group_id="B3" value="572"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="278"/>
                    <measurement group_id="B2" value="270"/>
                    <measurement group_id="B3" value="548"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="310"/>
                    <measurement group_id="B2" value="296"/>
                    <measurement group_id="B3" value="606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cigarettes smoked per day</title>
          <units>cigarettes/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.3" spread="9.99"/>
                    <measurement group_id="B2" value="19.7" spread="10.84"/>
                    <measurement group_id="B3" value="19.4" spread="10.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smokes within 30 minutes of waking</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="257"/>
                    <measurement group_id="B2" value="244"/>
                    <measurement group_id="B3" value="501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fagerstrom score (heavy nicotine dependence)</title>
          <description>The modified Fagerström test score for nicotine dependence ranges from 0 to 6. Scores of 4 or higher indicate heavy smoking dependence</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Motivation to quit smoking</title>
          <description>Motivation to quit smoking scores range from 0 to 10, with 10 indicating high motivation.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.3" spread="1.34"/>
                    <measurement group_id="B2" value="9.2" spread="1.60"/>
                    <measurement group_id="B3" value="9.3" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Confidence to quit smoking</title>
          <description>Confidence to quit smoking scores range from 0 to 10, with 10 indicating high confidence.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.1" spread="2.61"/>
                    <measurement group_id="B2" value="6.8" spread="2.45"/>
                    <measurement group_id="B3" value="7.0" spread="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Planning to quit smoking in the next 30 days</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="303"/>
                    <measurement group_id="B2" value="285"/>
                    <measurement group_id="B3" value="588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Quit attempted in the past 6 months</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous use of quit smoking medication</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="192"/>
                    <measurement group_id="B2" value="199"/>
                    <measurement group_id="B3" value="391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With 7-day Point Prevalence Abstinence From Cigarettes, Validated</title>
        <description>Participant-reported 7-day point prevalence abstinence from cigarettes, validated by salivary cotinine (&lt; 15ng/ml) or proxy. Participants who did not respond to the survey were considered current smokers.</description>
        <time_frame>12 months</time_frame>
        <population>Participants who were deceased or incarcerated at month 12 were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Centralized Disease Management (CDM)</title>
            <description>Experimental: 1 Centralized disease management
Centralized disease management (CDM): Centralized Disease Management (CDM) arm will receive smoking cessation counseling with coordination of pharmacotherapy with their insurance coverage and their health care provider</description>
          </group>
          <group group_id="O2">
            <title>Counseling (C)</title>
            <description>Experimental: 2 Counseling alone
Counseling (C): Counseling (C) arm will receive counseling without the care coordination services.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 7-day Point Prevalence Abstinence From Cigarettes, Validated</title>
          <description>Participant-reported 7-day point prevalence abstinence from cigarettes, validated by salivary cotinine (&lt; 15ng/ml) or proxy. Participants who did not respond to the survey were considered current smokers.</description>
          <population>Participants who were deceased or incarcerated at month 12 were excluded from analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.46</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With 7-day Point Prevalence Abstinence at 3 Months, Self-reported</title>
        <description>7-day point prevalence abstinence at 3 months, self-reported. Participants who did not respond were considered smokers.</description>
        <time_frame>3 months</time_frame>
        <population>Participants who were deceased or incarcerated at month 3 were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Centralized Disease Management (CDM)</title>
            <description>Experimental: 1 Centralized disease management
Centralized disease management (CDM): Centralized Disease Management (CDM) arm will receive smoking cessation counseling with coordination of pharmacotherapy with their insurance coverage and their health care provider</description>
          </group>
          <group group_id="O2">
            <title>Counseling (C)</title>
            <description>Experimental: 2 Counseling alone
Counseling (C): Counseling (C) arm will receive counseling without the care coordination services.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 7-day Point Prevalence Abstinence at 3 Months, Self-reported</title>
          <description>7-day point prevalence abstinence at 3 months, self-reported. Participants who did not respond were considered smokers.</description>
          <population>Participants who were deceased or incarcerated at month 3 were excluded from analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With 7-day Point Prevalence Abstinence at 6 Months, Self-reported</title>
        <description>7-day point prevalence abstinence at 6 months, self-reported. Participants who did not respond were considered smokers.</description>
        <time_frame>6 months</time_frame>
        <population>Participants who were deceased or incarcerated at month 6 were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Centralized Disease Management (CDM)</title>
            <description>Experimental: 1 Centralized disease management
Centralized disease management (CDM): Centralized Disease Management (CDM) arm will receive smoking cessation counseling with coordination of pharmacotherapy with their insurance coverage and their health care provider</description>
          </group>
          <group group_id="O2">
            <title>Counseling (C)</title>
            <description>Experimental: 2 Counseling alone
Counseling (C): Counseling (C) arm will receive counseling without the care coordination services.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 7-day Point Prevalence Abstinence at 6 Months, Self-reported</title>
          <description>7-day point prevalence abstinence at 6 months, self-reported. Participants who did not respond were considered smokers.</description>
          <population>Participants who were deceased or incarcerated at month 6 were excluded from the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With 7-day Point Prevalence Abstinence at 12 Months, Self-reported</title>
        <description>7-day point prevalence abstinence at 12 months, self-reported. Participants who did not respond were considered smokers.</description>
        <time_frame>12 months</time_frame>
        <population>Participants who were deceased or incarcerated at month 6 were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Centralized Disease Management (CDM)</title>
            <description>Experimental: 1 Centralized disease management
Centralized disease management (CDM): Centralized Disease Management (CDM) arm will receive smoking cessation counseling with coordination of pharmacotherapy with their insurance coverage and their health care provider</description>
          </group>
          <group group_id="O2">
            <title>Counseling (C)</title>
            <description>Experimental: 2 Counseling alone
Counseling (C): Counseling (C) arm will receive counseling without the care coordination services.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 7-day Point Prevalence Abstinence at 12 Months, Self-reported</title>
          <description>7-day point prevalence abstinence at 12 months, self-reported. Participants who did not respond were considered smokers.</description>
          <population>Participants who were deceased or incarcerated at month 6 were excluded from the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.48</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Utilization of Smoking Cessation Pharmacotherapy During First 6 Months</title>
        <time_frame>6 months</time_frame>
        <population>Excludes participants who were deceased or incarcerated at month 6, or who did not report on pharmacotherapy use.</population>
        <group_list>
          <group group_id="O1">
            <title>Centralized Disease Management (CDM)</title>
            <description>Experimental: 1 Centralized disease management
Centralized disease management (CDM): Centralized Disease Management (CDM) arm will receive smoking cessation counseling with coordination of pharmacotherapy with their insurance coverage and their health care provider</description>
          </group>
          <group group_id="O2">
            <title>Counseling (C)</title>
            <description>Experimental: 2 Counseling alone
Counseling (C): Counseling (C) arm will receive counseling without the care coordination services.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Utilization of Smoking Cessation Pharmacotherapy During First 6 Months</title>
          <population>Excludes participants who were deceased or incarcerated at month 6, or who did not report on pharmacotherapy use.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nicotine replacement therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prescription medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Utilization of Smoking Cessation Pharmacotherapy Between 6 and 12 Months</title>
        <time_frame>12 months</time_frame>
        <population>Includes only participants eligible to enter into Cycle 2 counseling (those who reported smoking at month 6). Excludes participants who were deceased or incarcerated at month 12, or who did not report on pharmacotherapy use.</population>
        <group_list>
          <group group_id="O1">
            <title>Centralized Disease Management (CDM)</title>
            <description>Experimental: 1 Centralized disease management
Centralized disease management (CDM): Centralized Disease Management (CDM) arm will receive smoking cessation counseling with coordination of pharmacotherapy with their insurance coverage and their health care provider</description>
          </group>
          <group group_id="O2">
            <title>Counseling (C)</title>
            <description>Experimental: 2 Counseling alone
Counseling (C): Counseling (C) arm will receive counseling without the care coordination services.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Utilization of Smoking Cessation Pharmacotherapy Between 6 and 12 Months</title>
          <population>Includes only participants eligible to enter into Cycle 2 counseling (those who reported smoking at month 6). Excludes participants who were deceased or incarcerated at month 12, or who did not report on pharmacotherapy use.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nicotine replacement therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prescription medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Centralized Disease Management (CDM)</title>
          <description>Experimental: 1 Centralized disease management
Centralized disease management (CDM): Centralized Disease Management (CDM) arm will receive smoking cessation counseling with coordination of pharmacotherapy with their insurance coverage and their health care provider</description>
        </group>
        <group group_id="E2">
          <title>Counseling (C)</title>
          <description>Experimental: 2 Counseling alone
Counseling (C): Counseling (C) arm will receive counseling without the care coordination services.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="310"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Oral discomfort</sub_title>
                <description>Tingling and blister associated with nicotine gum use</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Change in affect</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Sleep disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Tremors</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Local skin reaction</sub_title>
                <description>Itching or rash at nicotine patch site</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="310"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of bladder control</sub_title>
                <description>One time, for a few moments</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="310"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sharon Fitzgerald, MPH</name_or_title>
      <organization>University of Kansas Medical Center</organization>
      <phone>913-588-3488</phone>
      <email>sfitzgerald@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

